# Codex Review: medical_monitoring_source_preflight_revalidation_20260803

Date: 2026-08-03
Direct Codex work; no delegated agent, Hermes dispatch, or provider was used.

## Verdict

**Pass for this bounded read-only evidence slice; overall product remains blocked.**

## Boundary Check

- Product code change is isolated to
  `services/api/app/monitoring_source_batch_preflight_revalidation.py` and its
  focused test. The active-slice record is under
  `records/active_slices/medical_monitoring_source_preflight_revalidation_20260803/`.
- No runtime, source registry, adapter, frontend, SQLite, medical-writing,
  provider, browser, or real-project state was written.

## Codex Verification

- Reopened the current source-preflight JSON with exact file bytes/SHA:
  12889 bytes,
  `c11c6ac95fd0d8e4a94937b6ad8aa5bc8821fe16626c5706b467958ed8b5ec53`.
- Reopened all declared listing files. Report: `status=fresh`,
  `file_fresh=true`, `payload_valid=true`, `preflight_report_matches=true`,
  zero revalidation issues.
- Underlying source preflight remains `blocked`, 14 issues, 0 promoted eligible
  batches for RUX/MG-K10/MY009. B6/C14 remain blocked; 8911/5174 stayed stopped.
- Focused/adjacent regression: **51 passed**; Ruff and compile checks passed.
- After the final excluded-row correction, the focused/adjacent Python
  regression is **52 passed**. The existing medical-monitoring frontend
  contract suite also passed **22/22** Node test files; no frontend source was
  changed.

## Delegated-Agent Output Review

- The implementation reuses the existing typed `SourceBatchRecord` and
  `assess_source_batch_preflight` contract rather than duplicating admission
  logic. Null `batch_ref` rows are retained as excluded evidence and checked
  without inventing an identity.
- `fresh` is explicitly evidence freshness, not readiness; the persisted
  artifact records the distinction and keeps all authority flags false.
- No external model or external executable dependency was needed; this was a
  deterministic local integrity boundary.

## Residual Risk

- Residual source blockers: authorized B6 outcomes, disposition/CAS replay,
  legacy source-token revalidation, and two provenance-complete eligible batches
  per canonical project.
- Real Playwright/scientific acceptance, independent product-AI observations,
  UAT and commercial release remain unproven. This slice does not alter any of
  those gates.
